Evidence map›Paper›PMID 38829177›Full record

ArticleAmerican journal of medical genetics. Part A2024

Multicenter appraisal of comorbid TANGO2 deficiency disorder in patients with 22q11.2 deletion syndrome.

Laura D Owlett, Bianca Zapanta, Sarah E Sandkuhler, Elizabeth G Ames, Scott E Hickey, Samuel J Mackenzie, Joshua K Meisner

Abstract readMulticenter Study
In one paragraph

Article in American journal of medical genetics. Part A, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura D OwlettDepartment of Neurology, Division of Child Neurology, University of Rochester, Rochester, New York, USA.
Bianca ZapantaDepartment of Pediatrics, Section of Genetic and Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
Sarah E SandkuhlerDepartment of Pathology, University of Rochester, Rochester, New York, USA.
Elizabeth G AmesDepartment of Pediatrics, Division of Genetics, Metabolism & Genomic Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Scott E HickeyDepartment of Pediatrics, Section of Genetic and Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
Samuel J MackenzieDepartment of Neurology, Division of Child Neurology, University of Rochester, Rochester, New York, USA.
Joshua K MeisnerDepartment of Pediatrics, Division of Pediatric Cardiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-1049-8351

Funding

Child Neurologist Career Development Program (CNCDP)K12NS098482 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI SCHLAGGAR, BRADLEY L · 2016 to 2025
$26.2M
Advancing Child Health Through Cellular and Molecular BiologyK12HD028820 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Donna M. Martin · 2002 to 2026
$9.2M
NICHD NIH HHS K12 HD028820NIGMS NIH HHS 5K12HD028820NINDS NIH HHS K12 NS098482NINDS NIH HHS K12NS098482
6 · The paper itself

Abstract

TANGO2 deficiency disorder (TDD) is a rare, autosomal recessive condition caused by pathogenic variants in TANGO2, a gene residing within the region commonly deleted in 22q11.2 deletion syndrome (22q11.2DS). Although patients with 22q11.2DS are at substantially higher risk for comorbid TDD, it remains underdiagnosed within 22q11.2DS, likely due to overlapping symptomatology and a lack of knowledge about TDD. Initiation of B-vitamin supplementation may provide therapeutic benefit in TDD, highlighting the need for effective screening methods to improve diagnosis rates in this at-risk group. In this retrospective, multicenter study, we evaluated two cohorts of patients with 22q11.2DS (total N = 435) for possible comorbid TDD using two different symptom-based screening methods (free text-mining and manual chart review versus manual chart review alone). The methodology of the cohort 1 screening method successfully identified a known 22q11.2DS patient with TDD. Combined, these two cohorts identified 21 living patients meeting the consensus recommendation for TANGO2 testing for suspected comorbid TDD. Of the nine patients undergoing TANGO2 sequencing with del/dup analysis, none were ultimately diagnosed with TDD. Of the 12 deaths in the suspected comorbid TDD cohort, some of these patients exhibited symptoms (rhabdomyolysis, cardiac arrhythmia, or metabolic crisis) suspicious of comorbid TDD contributing to their death. Collectively, these findings highlight the need for robust prospective screening tools for diagnosing comorbid TDD in patients with 22q11.2DS.

Indexed as

DiGeorge SyndromeAdolescentAdultChildChild, PreschoolComorbidityFemaleHumansInfantMaleRetrospective StudiesYoung Adult22q11.2 deletion syndromeDiGeorge syndromedual molecular diagnosissudden deathTANGO2 deficiency disorder

Identifiers

PMID38829177
PMCPMC11502271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.